why choose us

First received: May 24, 2023

Clinical Trial: Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Long COVID

Study Type: INTERVENTIONAL


Official Title: An Exploratory, Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of an Anti-SARS-CoV-2 Monoclonal Antibody and Response to Treatment in Individuals With Long COVID (outSMART-LC)

Brief Summary: Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID.This mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs).This trial will study the safety and efficacy of AER002 to treat individuals with Long COVID in an adult population.

Read more